FemTech is often framed as a market trend. In this episode of “Clinical Capital Conversations”, Dr. Peter M. Kovacs explains why it is actually a long-overdue clinical correction.

Together with Roswitha Verwer, Founder and CEO of “YON E”, and Muskaan Bhan, Chief Clinical Officer, this conversation explores why women were historically excluded from clinical trials, how biased data still shape healthcare AI, and why continuous measurement is changing medicine.

This episode is for investors, founders, and healthcare leaders who care about execution, responsibility, and long-term impact, not shortcuts.

Timecode:

00:00 Welcome and Introduction

00:50 Progress and Achievements in FemTech

02:16 Strategic Planning and Teamwork

05:18 Challenges in FemTech and AI Development

08:42 Importance of Continuous Data Tracking

12:49 Ethical Considerations and Long-Term Goals

16:20 FemTech Industry Trends and Future Outlook

20:29 Navigating Advisory Roles in a Regulated Era

20:48 The Rise of FemTech and Female Health Initiatives

22:38 Building a Supportive FemTech Community

23:19 Challenges in FemTech Investment

24:34 Investor Conversations and Strategies

30:21 The Importance of Team and Personal Connections

33:08 Future Plans and Closing Remarks

Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.

Links:

Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/

Peter M. Kovacs Personal Website:https://www.petermkovacs.com/

PMK Group Website: https://www.pmk-group.com/

Guests:

Roswitha Verwer LinkedIn: https://www.linkedin.com/in/roswitha-verwer-b2b636137/

Roswitha Verwer Personal Website: https://www.roswithaverwer.com/

Dr. Muskaan Bhan: https://www.linkedin.com/in/dr-muskaan-bhan-9b7123120/